CZ20014613A3 - Terapeutická činidla - Google Patents

Terapeutická činidla Download PDF

Info

Publication number
CZ20014613A3
CZ20014613A3 CZ20014613A CZ20014613A CZ20014613A3 CZ 20014613 A3 CZ20014613 A3 CZ 20014613A3 CZ 20014613 A CZ20014613 A CZ 20014613A CZ 20014613 A CZ20014613 A CZ 20014613A CZ 20014613 A3 CZ20014613 A3 CZ 20014613A3
Authority
CZ
Czechia
Prior art keywords
formula
compound
treatment
pharmaceutically acceptable
obesity
Prior art date
Application number
CZ20014613A
Other languages
Czech (cs)
English (en)
Inventor
David John Heal
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of CZ20014613A3 publication Critical patent/CZ20014613A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ20014613A 1999-06-24 2000-06-16 Terapeutická činidla CZ20014613A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents

Publications (1)

Publication Number Publication Date
CZ20014613A3 true CZ20014613A3 (cs) 2003-04-16

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20014613A CZ20014613A3 (cs) 1999-06-24 2000-06-16 Terapeutická činidla

Country Status (21)

Country Link
EP (1) EP1187606A1 (xx)
JP (1) JP2003503349A (xx)
KR (1) KR20020015357A (xx)
CN (1) CN1358092A (xx)
AU (1) AU5533200A (xx)
BG (1) BG106180A (xx)
BR (1) BR0011880A (xx)
CA (1) CA2375972A1 (xx)
CZ (1) CZ20014613A3 (xx)
GB (1) GB9914744D0 (xx)
HK (1) HK1049278A1 (xx)
HU (1) HUP0201878A3 (xx)
IL (1) IL147079A0 (xx)
MX (1) MXPA01012936A (xx)
NO (1) NO20016224L (xx)
PL (1) PL352402A1 (xx)
RU (1) RU2229289C2 (xx)
SK (1) SK18242001A3 (xx)
TR (1) TR200103699T2 (xx)
WO (1) WO2001000205A1 (xx)
ZA (1) ZA200109989B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
JP2010503709A (ja) * 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
PL352402A1 (en) 2003-08-25
HUP0201878A3 (en) 2005-04-28
RU2229289C2 (ru) 2004-05-27
NO20016224D0 (no) 2001-12-19
ZA200109989B (en) 2003-02-26
AU5533200A (en) 2001-01-31
BR0011880A (pt) 2002-03-19
HK1049278A1 (zh) 2003-05-09
NO20016224L (no) 2002-02-12
TR200103699T2 (tr) 2002-04-22
IL147079A0 (en) 2002-08-14
MXPA01012936A (es) 2004-04-21
GB9914744D0 (en) 1999-08-25
SK18242001A3 (sk) 2003-02-04
WO2001000205A1 (en) 2001-01-04
EP1187606A1 (en) 2002-03-20
JP2003503349A (ja) 2003-01-28
BG106180A (en) 2002-08-30
KR20020015357A (ko) 2002-02-27
CN1358092A (zh) 2002-07-10
HUP0201878A2 (hu) 2003-08-28
CA2375972A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
CA2367666C (en) Method of treating eating disorders
EP1039900B1 (en) Pharmaceutical composition containing sibutramine and orlistat
US6376553B1 (en) Treatment of pain
WO2000056309A1 (en) Method of treating sexual dysfunction
US6376552B1 (en) Treatment of gallstones
CZ20014613A3 (cs) Terapeutická činidla
US6441046B1 (en) Control of metabolism
US6232347B1 (en) Treatment of osteoarthritis
US6346549B1 (en) Treatment of pharmacology of drug misuse and other addictive disorders
AU773490B2 (en) Treatment of osteoarthritis
CA2366652A1 (en) Treatment of pulmonary hypertension
EP1171106A1 (en) Treatment of certain cancers associated with weight gain
WO2000056308A1 (en) Prevention of cardiovascular disease
WO2000056307A1 (en) Treatment of hiatial hernia
CA2368416A1 (en) Treatment of gallstones
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat